Arcellx

Regulatory and manufacturing milestones are inherently lumpy and binary. Arcellx experienced a partial clinical hold in 2023 that was later lifted after protocol modifications, underscoring tail risks in development. While the BLA is on file for 4L+, outcomes depend on pre‑approval inspections, manufacturing readiness and benefit‑risk reviews.

Revenue timing and shape remain uncertain due to capacity ramp, center activation and competition from established CAR‑Ts in earlier lines.